Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Learn more about:
Related Clinical Trial
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Managed Access Program Supporting Patient Access to Tebentafusp Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Official Title

Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma

Brief Summary

      This randomized phase II trial studies how well cabozantinib-s-malate works compared with
      temozolomide or dacarbazine in treating patients with melanoma of the eye (ocular melanoma)
      that has spread to other parts of the body and cannot be removed by surgery.
      Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as temozolomide and dacarbazine,
      work in different ways to stop the growth of tumor cells, either by killing the cells, by
      stopping them from dividing, or by stopping them from spreading. It is not yet known whether
      cabozantinib-s-malate works better than temozolomide or dacarbazine in treating patients with
      melanoma of the eye.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. Compare the progression-free survival rate at 4 months (PFS4) of patients with ocular
      melanoma treated with cabozantinib-s-malate (cabozantinib) or temozolomide (or dacarbazine).

      SECONDARY OBJECTIVES:

      I. Estimate the distribution of progression-free survival (PFS) times. II. Estimate the
      distribution of overall survival (OS) times. III. Estimate the confirmed response rate as
      determined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

      IV. Assess the safety of these agents by examining the toxicity profile. V. Correlate the
      response of MET molecular status.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive cabozantinib-s-malate orally (PO) once daily (QD) on days 1-28.
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      ARM II: Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in
      the absence of disease progression or unacceptable toxicity. If temozolomide is not
      available, patients receive dacarbazine intravenously (IV) over 15-60 minutes on day 1.
      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 12 weeks for 2 years.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Proportion of Patients Without a Progression Free Survival Event at 4 Months (PFS4)

Secondary Outcome

 Confirmed Response Rate as Determined by the RECIST Criteria (Version 1.1)

Condition

Recurrent Uveal Melanoma

Intervention

Cabozantinib S-malate

Study Arms / Comparison Groups

 Arm I (cabozantinib-s-malate)
Description:  Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

47

Start Date

July 31, 2013


Primary Completion Date

October 21, 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically or cytologically confirmed uveal melanoma that is metastatic or
             unresectable; if histologic or cytologic confirmation of the primary is not available,
             confirmation of the primary diagnosis of uveal melanoma by the treating investigator
             can be clinically obtained, as per standard practice for uveal melanoma; pathologic
             confirmation of diagnosis will be performed at the participating site

          -  Measurable disease defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded for non-nodal lesions and
             short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm
             with spiral computed tomography (CT) scan or magnetic resonance imaging (MRI)

          -  Prior systemic therapies allowed, except for those treatments directed toward, or with
             activity against, c-Met or vascular endothelial growth factor/receptor (VEGF/R), and
             the chemotherapy agents temozolomide and dacarbazine; prior treatment must have been
             no earlier than 3 weeks prior to starting treatment with cabozantinib with exceptions
             noted below and the following: at least 4 weeks since prior hepatic infusion or at
             least 2 weeks since radiation therapy

          -  No cytotoxic chemotherapy including investigational cytotoxic chemotherapy or biologic
             agents (e.g., cytokines or antibodies) within the last 3 weeks, or
             nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment; at
             least 6 weeks must have elapsed if the last regimen included an anti-cytotoxic
             T-lymphocyte antigen 4 (CTLA4) antibody; patients must have experienced disease
             progression on their prior therapy in the opinion of the treating investigator

          -  No prior radiation therapy within the last 4 weeks, except as below

               -  To the thoracic cavity, abdomen, or pelvis within 12 weeks before the first dose
                  of study treatment, or has ongoing complications, or is without complete recovery
                  to < grade 1 toxicity

               -  To bone or brain metastasis within 14 days before the first dose of study
                  treatment

               -  To any other site(s) within 28 days before the first dose of study treatment

               -  Prior radiation treatment may have included no more than 3000 centigray (cGy) to
                  fields including substantial bone marrow

          -  No prior radionuclide treatment within 6 weeks of the first dose of study treatment

          -  No prior treatment with a small molecule kinase inhibitor or a hormonal therapy within
             14 days or 5 half-lives (whichever is longer)

          -  No concomitant anti-cancer therapy unless specified above

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

          -  A corrected QT interval calculated by the Fridericia formula (QTcF) =< 500 ms within
             28 days before randomization; Note: if initial QTcF is found to be > 500 ms, two
             additional electrocardiograms (EKGs) separated by at least 3 minutes should be
             performed; if the average of these three consecutive results for QTcF is =< 500 ms,
             the patient meets eligibility in this regard

          -  Common Terminology Criteria for Adverse Events (CTCAE) recovered to baseline or CTCAE
             =< grade 1 from toxicity due to all prior therapies except alopecia and other
             non-clinically significant adverse events (AEs)

          -  No active brain metastases or epidural disease; patients with brain metastases
             previously treated with whole brain radiation or radiosurgery or patients with
             epidural disease previously treated with radiation or surgery who are asymptomatic and
             do not require steroid treatment for at least 2 weeks before starting study treatment
             are eligible; neurosurgical resection of brain metastases or brain biopsy is permitted
             if completed at least 12 weeks before starting study treatment; baseline brain imaging
             with contrast-enhanced CT or MRI scans for patients with known brain metastases is
             required to confirm eligibility

          -  No clinically significant gastrointestinal bleeding within 24 weeks before the first
             dose of study treatment

          -  No hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 12 weeks before the
             first dose of study treatment

          -  No signs indicative of pulmonary hemorrhage within 12 weeks before the first dose of
             study treatment

          -  No prior radiographic evidence of cavitating pulmonary lesion(s)

          -  No tumor in contact with, invading or encasing any major blood vessels

          -  No evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach,
             small or large bowel, rectum or anus), or any evidence of endotracheal or
             endobronchial tumor within 28 days before the first dose of treatment

          -  The patient may not have uncontrolled, significant intercurrent or recent illness
             including, but not limited to, the following conditions:

               -  Cardiovascular disorders including:

                    -  Congestive heart failure (CHF): New York Heart Association (NYHA) class III
                       (moderate) or class IV (severe) at the time of screening

                    -  Concurrent uncontrolled hypertension defined as sustained blood pressure
                       (BP) > 140 mmHg systolic, or > 90 mmHg diastolic despite optimal
                       antihypertensive treatment within 7 days of the first dose of study
                       treatment

                    -  Any history of congenital long QT syndrome

                    -  Any of the following within 24 weeks before the first dose of study
                       treatment:

                         -  Unstable angina pectoris

                         -  Clinically-significant cardiac arrhythmias

                         -  Stroke (including transient ischemic attack [TIA], or other ischemic
                            event)

                         -  Myocardial infarction

                         -  Thromboembolic event requiring therapeutic anticoagulation (Note:
                            patients with a venous filter [e.g. vena cava filter] are not eligible
                            for this study)

               -  Gastrointestinal disorders particularly those associated with a high risk of
                  perforation or fistula formation including:

                    -  Any of the following within 28 days before the first dose of study treatment

                         -  Intra-abdominal tumor/metastases invading GI mucosa

                         -  Active peptic ulcer disease

                         -  Inflammatory bowel disease (including ulcerative colitis and Crohn's
                            disease), diverticulitis, cholecystitis, symptomatic cholangitis or
                            appendicitis

                         -  Malabsorption syndrome

                    -  Any of the following within 24 weeks before the first dose of study
                       treatment:

                         -  Abdominal fistula

                         -  Gastrointestinal perforation

                         -  Intra-abdominal abscess; Note: complete resolution of an
                            intra-abdominal abscess must be confirmed prior to initiating treatment
                            with cabozantinib even if the abscess occurred more that 24 weeks
                            before the first dose of study treatment

                         -  Bowel obstruction or gastric outlet obstruction

               -  Other clinically significant disorders such as:

                    -  Serious non-healing wound/ulcer/bone fracture within 28 days before the
                       first dose of study treatment

                    -  History of organ transplant

                    -  Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days
                       before the first dose of study treatment

                    -  History of major surgery as follows:

                         -  Major surgery in past 8 weeks of the first dose of cabozantinib if
                            there were no wound healing complications or within 24 weeks of the
                            first dose of cabozantinib if there were wound complications

                         -  Minor surgery within 4 weeks of the first dose of cabozantinib if there
                            were no wound healing complications or within 12 weeks of the first
                            dose of cabozantinib if there were wound complications

                         -  In addition, complete wound healing from prior surgery must be
                            confirmed at least 28 days before the first dose of cabozantinib
                            irrespective of the time from surgery

                    -  Active infection requiring systemic treatment within 28 days before the
                       first dose of study treatment

          -  No concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin
             or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or antiplatelet
             agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1
             mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted; please
             note that drugs that strongly induce or inhibit cytochrome P450 family 3, subfamily A,
             polypeptide 4 (CYP3A4) or are associated with a risk of Torsades are not allowed;
             chronic concomitant treatment of CYP3A4 inducers is not allowed (e.g., dexamethasone,
             phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St.
             John's wort); as part of the enrollment/informed consent procedures, the patient will
             be counseled on the risk of interactions with other agents, and what to do if new
             medications need to be prescribed or if the patient is considering a new
             over-the-counter medicine or herbal product; the following drugs are strong inhibitors
             of CYP3A4 and are not allowed during the treatment with cabozantinib:

               -  Boceprevir

               -  Indinavir

               -  Nelfinavir

               -  Lopinavir/ritonavir

               -  Saquinavir

               -  Telaprevir

               -  Ritonavir

               -  Clarithromycin

               -  Conivaptan

               -  Itraconazole

               -  Ketoconazole

               -  Mibefradil

               -  Nefazodone

               -  Posaconazole

               -  Voriconazole

               -  Telithromycin

               -  Drugs with possible or conditional risk of torsades should be used with caution
                  knowing that cabozantinib could prolong the QT interval

          -  Patients who are pregnant or nursing are not eligible; women of child bearing
             potential must have a negative serum or urine pregnancy test within 16 days prior to
             registration; women of child-bearing potential include:

               -  Any female who has experienced menarche and who has not undergone surgical
                  sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy)
                  or is not postmenopausal (defined as amenorrhea >= 12 consecutive months)

               -  Women on hormone replacement therapy (HRT) with documented serum follicle
                  stimulating hormone (FSH) level > 35m IU/mL

               -  Women who are using oral, implanted or injectable contraceptive hormones or
                  mechanical products such as an intrauterine device or barrier methods (diaphragm,
                  condoms, spermicides) to prevent pregnancy or practicing abstinence or where
                  partner is sterile (e.g., vasectomy)

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to cabozantinib, temozolomide and dacarbazine

          -  Absolute neutrophil count >= 1,500/mcL

          -  Platelets >= 100,000/mcL

          -  Total bilirubin =< 1.5 × upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 5.0 × institutional upper limit of normal (for patients with metastases); AST
             (SGOT)/ALT (SGPT) =< 2.5 × institutional upper limit of normal (for patients without
             metastases)

          -  Serum creatinine =< 1.5 × ULN, OR calculated creatinine clearance >= 30 mL/minute
             (modified Cockcroft and Gault formula)

          -  Hemoglobin >= 9 g/dL

          -  Serum albumin >= 2.8 g/dL

          -  Urine protein/creatinine ratio (UPCR) =< 1; if urine/protein creatinine (UPC) >= 1,
             then a 24-hour urine protein must be assessed; eligible patients must have a 24-hour
             urine protein value < 1 g/L

          -  Thyroid-stimulating hormone (TSH) within normal limits (WNL); supplementation is
             acceptable to achieve a TSH WNL; in patients with abnormal TSH however free T4 and
             free thyroxine index (FTI) are normal and patient is clinically euthyroid, patient is
             eligible

          -  Prothrombin time (PT)/international normalized ratio (INR) must be =< 1.2 x the
             laboratory ULN

          -  No clinical or radiographic evidence of pancreatitis
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Jason J Luke, , 

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT01835145

Organization ID

NCI-2013-00821

Secondary IDs

NCI-2013-00821

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)

Collaborators

 Exelisis

Study Sponsor

Jason J Luke, Principal Investigator, Alliance for Clinical Trials in Oncology


Verification Date

September 2021